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H1-receptor antagonists (H1-antihistamines) that competi-
tively block histamine at H1-receptors have been used in the
treatment of allergic conditions for many years. Clinically useful
H1-antihistamines such as phenbenzamine, pyrilamine, and
diphenhydramine were introduced in the 1940s. Currently, H1
antihistamines constitute the second most commonly used class
of medications after antibiotics, with more than 40 varieties used
in clinical practice worldwide [1].
H1-antihistamines are traditionally classiﬁed into six groups,
based on their chemical structure to [2]:
a- Alkylamines: drugs within this group typically possess signif-
icant sedative actions, although paradoxical stimulation can
occur, especially in children. Brompheniramine and chlor-
pheniramine are typical alkylamine antihistamines.
b- Monoethanolamines: they have pronounced sedative and
antimuscarinic actions but a low incidence of gastro-
intestinal effects. Examples include clemastine and
diphenhydramine.
c- Ethylenediamines: these antihistamines are selective H1-
antagonist. They cause moderate sedation (despite having
weak CNS effects), gastric disturbances, and skin sensitiza-
tion. Antazoline, mepyramine and tripelennamine are
examples.
d- Phenothiazines: phenothiazine antihistamines have signiﬁ-
cant sedative, and pronounced antiemetic and antimuscari-
nic effects. Promethazine is a typical example.
e- Piperazines: this group of antihistamines possesses moderate
sedative and signiﬁcant antiemetic actions. Piperazine deriv-
atives include cetirizine, cyclizine, and hydroxyzine. Cetiri-
zine causes less sedation than other members of this group.
f- Piperidines: they cause moderate or low sedation and are
highly selective for H1 receptors. Examples include azata-
dine, cyproheptadine, and non-sedating antihistamines
(astimazole, desloratadine, ebastine, fexofenadine, lorata-
dine, and terfenadine).
This classiﬁcation is, however, of limited clinical relevance, and
currently H1-antihistamines are classiﬁed as [1]:
a- First generation; also known as ‘sedating antihistamines’,
First-generation H1 antihistamines such as alimemazine, chlor-
phenamine, clemastine, cyproheptadine, hydroxyzine, and pro-
methazine are non-selective in binding to the H1 receptor. Most
of these drugs have weak antimuscarinic anticholinergic effects,
some have alpha-adrenergic blocking effects (promethazine),
and others can inhibit both histamine and 5-hydroxytryptamine
activity (cyproheptadine). Owing to their lipophilicity, relatively
low molecular weight, and lack of recognition by the P-glycopro-
tein efﬂux pump, ﬁrst-generation H1 antihistamines readily pen-
etrate the non-fenestrated capillaries of the central nervous
system (blood brain barrier) and bind to central H1 receptors,
interfering with the actions of histamine on these receptors.
b- Second generation, which are relatively non-sedating. Second-
generation H1-antihistamines such as cetirizine (CTZ), Ebastine
(EBS), ketotifen (KET), loratadine (LOR) are newer drugs that are
much more selective for peripheral H1 receptors as opposed to
the central nervous system H1 receptors and cholinergic recep-
tors. This selectivity signiﬁcantly reduces the occurrence of
adverse drug reactions, such as sedation, while still providing
effective relief of allergic conditions. The reason for their periph-
eral selectivity is that most of these compounds are zwitterionic
at physiological pH (around pH 7.4). As such, they are very polar,meaning that they do not cross the blood–brain barrier and act
mainly outside the central nervous system, that is why they
produce very little or no sedation.
c- Third generation antihistamines includes some newly pro-
duced non-sedating antihistamines that are selective isomers or
active metabolites of older second-generation antihistamines,
and intended to have increased efﬁcacy with fewer adverse drug
reactions. Third-generation H1-antihistamines such as deslorata-
dine, that results via an oxidative process of LOR. This is metabolite
does not reach the CNS in signiﬁcant concentrations. Another drug
belongs to this group is fexofenadine (FXD) which is the carboxylic
acid metabolite of terfenadine. FXD accounts for the antihistaminic
properties of terfenadine but does not have the antiarrhythmic side
effects of terfenadine.
The older ﬁrst generation antihistamines are associated with
troublesome sedative and antimuscarinic effects, and are often
termed ‘sedating antihistamines’. The newer generations of
antihistamines, which are essentially devoid of these effects,
are correspondingly termed as ‘non-sedating antihistamines’
(NSAs) [2].
NSAs are of potential value in the management of allergic
rhinitis in which they relieve nasal and conjunctival itching,
sneezing and rhinorrhoea. They are also useful in the treatment
of acute and chronic urticaria [1]. NSAs down regulate allergic
inﬂammation directly by interfering with histamine action at
H1-receptors on sensory neurons and small blood vessels.
They also decrease the antigen presentation, expression of
pro-inﬂammatory cytokines and cell adhesion molecules, and
chemotaxis. In a concentration-dependent manner, they inhibit
mast cell activation and histamine release; although their
mechanisms of action involved have not yet been fully delin-
eated, down regulation of the accumulated intracellular calcium
ion seems to play a role [3].
In the last few years, there was no comprehensive review pub-
lished covering all different analytical techniques used for the
determination of NSAs. So the present review comprises references
covering the period from 1991 till now. The high importance of this
class of drugs prompted us to review the most important recent
methods for their analysis in pure forms, in different pharmaceuti-
cal dosage forms and in biological ﬂuids.2. Chemistry
Our review is concerned with the second- and third-generation
antihistamines which have quite similar pharmacological effects.
We selected the commonly prescribed NSAs, namely cetirizine
(CTZ), ebastine (EBS), fexofenadine (FXD), ketotifen (KET) and
loratadine (LOR). Chemical structures, nomenclatures and molecu-
lar weights of these drugs are shown in Table 1 [4]. Structurally
they all have the same nucleus (piperidine) except cetirizine which
is a diaryl substituted piperazine [5].3. Pharmacokinetics of NSAs
The pharmacokinetics of the H1 antihistamines has proved to
be of great importance especially for the second- and third-
generation drugs. Since pharmacokinetics demonstrates the lack
of their sedative effect due to their poor distribution to the
CNS [6]. Several second- and third-generation drugs are long-act-
ing with duration of action from 12 to 24 h. Table 2 summarizes
the differences in route of administration, bioavailability,
metabolism, plasma protein binding and excretion between the
individual compounds [7,8].
Table 1
Chemical structures of the studied non-sedating antihistamines (NSAs).
Drug (abbrev.) Chemical structure Chemical name M.Wt. Generation
Cetirizine (CTZ) (±)[2[4[(4Chlorophenyl) phenyl methyl]-1-piperazinyl]ethoxy]acetic acid 388.89 2nd
Ebastine (EBS) 4-(4-Benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl) butan-1-one 469.658 2nd
Fexofenadine
(FXD)
(RS)-2-[4-[1-Hydroxy-4-[4-(hydroxy- diphenyl-methyl)-1-piperidyl]butyl]phenyl]-2-
methyl-propanoic acid
501.656 3rd
Ketotifen (KET) 4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-
10-one
309.426 2nd
Loratadine
(LOR)
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-
piperidine carboxylate
382.88 2nd
M.E. El-Kommos et al. / Analytical Chemistry Research 3 (2015) 1–12 34. Ofﬁcial methods of analysis
The European pharmacopoeia 2014 [9] and British pharmaco-
poeia 2009 [10] have introduced titrimetric, spectrophotometric
and chromatographic methods for determination of CTZ, EBS,
FXD, KET and LOR (Table 3). United States pharmacopoeia (USP)
2008 [11] has introduced chromatographic methods (High Perfor-
mance Liquid Chromatography HPLC and High Performance Thin
Layer Chromatography HPTLC) for separation and quantitative
determination of FXD and LOR in pure and pharmaceutical dosage
forms. USP 2008 suggested an HPTLC method for assay of FXD and
pseudoephedrine hydrochloride extended-release tablets by using
silica gel plate, a mixture of toluene:dehydrated alcohol:ammo-
nium hydroxide (50:45:5, v/v/v) as a developing solvent system
and UV detection at 254 nm. Also, LOR oral solution and tablets
are estimated by HPTLC, using ethyl ether and diethylamine
(40:1, v/v) as a developing solvent system.
The reported HPLC methods in USP (2008) for separation and
quantitative determination of FXD and LOR in pure and pharma-
ceutical dosage forms are summarized in Table 4.5. Reported methods of analysis
5.1. Titrimetric methods
Titrimetric assay for the determination of CTZ has been devel-
oped, based on the measurement of the chloride from hydrochlo-
rides using diphenylcarbazone-bromothymol blue as indicator
[12]. A coulometric titration of KET in tablets has been also
reported, involving the reaction of KET with iodine in alkaline med-
ium using biamperometric end-point detection [13].
5.2. Spectroscopic methods
5.2.1. Ultraviolet spectrophotometric methods
Direct UV, derivative and chemometric spectrophotometric
methods have been used for the analysis of different NSAs in their
pure and pharmaceutical dosage forms. Simple UV spectrophoto-
metric and absorbance ratio methods were developed for the esti-
mation of CTZ hydrochloride in combination with ambroxol
hydrochloride in tablets [14–16]. UV spectrophotometric methods
4 M.E. El-Kommos et al. / Analytical Chemistry Research 3 (2015) 1–12were applied to the determination of LOR hydrochloride in tablets
and suspension [17,18]. Derivative spectrophotometric method
was used for the assay of three binary mixtures of pseudoephed-
rine with CTZ, FXD and LOR. This method is based on the use of
the ﬁrst derivative of the ratio spectrum [19]. CTZ was determined
by the measurement of its ﬁrst (1D) and second (2D) derivative
amplitudes at 239 nm and 243–233 nm, respectively [20]. The
acid-base properties of CTZ have been studied using multiwave-
length spectrophotometric titration method [21]. On the other
hand, UV-spectrophotometric absorption correction and simulta-
neous equation methods have been developed for the analysis of
EBS and Phenylephrine HCl in bulk and combined tablet [22].
Derivative spectrophotometry, 1D and 2D were used to measure
FXD in the presence of its alkaline or acidic oxidative degradation
products [23]. A method for the determination of FXD and pseudo-
ephedrine in their combined tablet formulation has been devel-
oped, employing the partial least squares analysis of spectral
data in their pharmaceutical preparation [24]. LOR and pseudoe-
phedrine sulfate were estimated by ﬁrst-, second- and ratio spectra
derivative spectrophotometric methods [25–28]. Furthermore, sta-
bility-indicating methods have been reported for the determina-
tion of LOR in the presence of its degradation products developed
by 1D ratio spectra, at 236, 262.4 and 293.2 nm and by second-
derivative spectrophotometry, at 266 nm [29]. Also, 2D spectro-
photometry has been described for the simultaneous determina-
tion of LOR and montelukast in their pharmaceutical
formulations, the zero-crossing technique was applied at
276.1 nm for LOR, but tangent method was used at 359.7 nm for
montelukast [30].
5.2.2. Visible spectrophotometric methods
The reported visible spectrophotometric methods for the deter-
mination of NSAs could be classiﬁed according to the following
reactions:
(I) Charge-transfer complexation.
(II) Redox reactions.
(III) Ion pair formation.
(IV) Miscellaneous.
5.2.2.1. Charge-transfer complexation. Charge transfer complexation
has been reported for the spectrophotometric determination of the
cited NSAs, where they act as n-donors with either p-acceptor or
r-acceptor.
El Walily et al. [20] described a spectrophotometric procedure
for the assay of CTZ sodium based on measuring the absorbanceTable 2
Pharmacokinetic properties of some non-sedating antihistamines (NSAs).
Drug CTZ EBS
Pharmacokinetic data
Route of administration Oral Oral
Bioavailability Well absorbed Well absorbed
Metabolism Excreted mainly
unchanged
Hepatic (CYP3A4-
mediated), to carebastine
Elimination half-life (h) 8.3 15–19
Duration of action (h) 12–24 24
Time to maximum plasma
concentration (h) after
single dose
1.0 ± 0.5 2
Plasma Protein binding % 93% Greater than 95%
Excretion Urine (mainly), hepatic
or excrement (Small
amounts)
2–3% renal/more than 90%
fecal as metabolite
(carebastine)of the chromogen formed between CTZ sodium salt in polar solvent
(dimethyl formamide) and chloranil at 556 nm. On the other hand,
FXD hydrochloride was determined by 4-chloro-7-nitrobenzo-2-
oxa-1,3-diazole (NBD-Cl), forming an orange colored product mea-
sured at 469 nm [31]. El-Kousy and Bebawy [32] developed a
method for the determination of KET and LOR based on the forma-
tion of radical ion using 2,3-dichloro-5,6-dicyano-p-benzoquinone
(DDQ), the color formed was measured at 588 nm. LOR was esti-
mated by charge-transfer complex formation with Chloranilic acid
(CLA) as a p-acceptor, and the resultant complex was measured at
520 nm [33].
5.2.2.2. Redox reactions. Narayana [34] proposed a spectrophoto-
metric assay of FXD hydrochloride in bulk and dosage forms using
chloramine-T (CAT) and two dyes malachite green (MAG) and
xylene cyanol FF (XFF). This method entailed the addition of a
known excess of CAT to FXD hydrochloride in acidic medium fol-
lowed by the determination of the residual oxidant by reacting it
with a ﬁxed amount of MAG, measuring the absorbance at
615 nm, or 612 nm with XFF. On the other hand, KET fumarate
was determined in bulk and pharmaceutical samples by the forma-
tion of colored species by the coupling of the diazotized sulpha-
nilamide with the drug at 520 nm or by oxidizing it with excess
N-bromo-succinimide (NBS) and determining the consumed NBS
with decrease in color intensity of celestine blue at 540 nm or by
the reduction of Folin–Ciocalteau reagent at 720 nm [35].
5.2.2.3. Ion pair formation. El-Kommos et al. [36] proposed a simple
spectrophotometric method for determination of CTZ, EBS, FXD,
KET and LOR in pharmaceutical preparations using erythrosine B.
The formed pink-colored complex was measured at 550 nm with-
out solvent extraction. Two spectrophotometric methods were
reported for determination of CTZ, FXD and LOR in pure and com-
mercial dosage forms using ion pair complexation [37]. The ﬁrst
method is based on the reaction of these drugs with bromocresol
purple dye to form extractable ion-pair complex and subsequently
measured spectrophotometrically. Secondly, eosin gives ion-pair
complex, measurable directly without extraction. An Extractive
spectrophotometric method was developed for the assay of CTZ
hydrochloride in bulk drug, pharmaceutical preparations, and
biological ﬂuids [38]. The method is based on the formation of a
chloroform soluble ion-pair complex using thymol blue in an acidic
buffer at 413 nm. Also, CTZ dihydrochloride present in pure and
different pharmaceutical preparations was estimated by the
formation of extractable yellow ion-pair complex with methyl
orange at pH 4.0, measured at 424.5 nm [39]. Furthermore, CTZ
hydrochloride in pharmaceutical formulations was determinedFXD KET LOR
Oral Oral/ophthalmic Oral
30–41% 60% Almost 100%
Hepatic CYP450 Hepatic CYP3A4, oxidation Hepatic CYP2D6,
CYP3A4
14.4 12 8
12–24 12 24
1–3 2–4 1.2 ± 0.3
60–70% 75% 97–99%
Fecal (80%) and
renal (11%) as
unchanged drug
Mainly renal as inactive
metabolite with a small amount
of unchanged drug
40% as conjugated
metabolites into
urine
Similar amount
into the feces
Table 3
Ofﬁcial methods of analysis of the studied NSAs in European pharmacopoeia 2014 and British pharmacopoeia 2009.
Method Cetirizine Ebastine Fexofenadine Ketotifen Loratadine
Titrimetry Titrant 0.1 M NaOH 0.1 M HClO4 0.2 M HClO4 0.3 M HClO4
End
point
Potentiometrically Potentiometrically Potentiometrically Potentiometrically
UV/visible
spectrophotometry
kmax at 231 nm
Thin-layer
chromatography
– Stationary phase, TLC
silica gel GF254
– Mobile phase, ammo-
nia/methanol/methy-
lene chloride (1:10:90,
v/v/v)
– Detection, UV at
254 nm
– Stationary phase,
cellulose
– Mobile phase,
water/anhydrous
formic acid/di-
isopropyl ether
(3:7:90, v/v/v)
– Detection, UV at
254 nm, Spraying
with KMnO4 in
1.4%v/v H2SO4, in
daylight by
transparency
Liquid chromatography With related substances:
– Stationary phase; silica
gel
– Mobile phase; dilute
H2SO4/water/ acetoni-
trile (0.4:6.6:93, v/v/v)
– Detection; at 230 nm
With related
substances:
– Stationary phase;
nitrile silica gel
– Mobile phase;
acetonitrile/phos-
phoric acid
adjusted to pH
5.0 with NaOH
solution (35:65,
v/v)
– Detection; at
210 nm
– Stationary phase;
silica gel BC
– Mobile phase; aceto-
nitrile/a buffer (gla-
cial acetic acid and
ammonia, pH 4)
(20:80 v/v)
– Detection; at
220 nmWith related
substances:
– Stationary phase;
phenylsilyl silica gel
– Mobile phase; aceto-
nitrile/a buffer (gla-
cial acetic acid and
ammonia, pH 4)/tri-
ethylamine
(350:650:3, v/v/v)
– Detection; at 220 nm
With related
substances:
– Stationary phase;
octadecylsilyl sil-
ica gel
– Mobile phase; (A)
triethylamine/
water.
(B)triethylamine/
– methanol
– Detection; at
297 nm
With related substances:
– Stationary phase; spher-
ical end-capped octade-
cylsilyl silica gel with
very low silanol activity
– Mobile phase; metha-
nol/potassium dihydro-
gen phosphate (pH
2.80 ± 0.05) with phos-
phoric acid/acetonitrile
(30:35:40, v/v/v)
– Detection; at 220 nm
Gas chromatography – Stationary phase; poly
(dimethyl) siloxane
– Carrier gas; helium
– Detection; ﬂame
ionization
Table 4
HPLC methods in USP (2008) for determination of FXD and LOR.
Drug Column/stationary phase Mobile phase Detection
FXD 4.6 mm  25 cm, packing phenyl groups bonded with porous silica Phosphate-perchlorate buffer and acetonitrile
(65:35, v/v) as a mobile phase adjusted to pH 2.0
with phosphoric acid
UV,
220 nm
FXD hydrochloride
capsules
4.6 mm  10 cm, packing octadecyl silane bonded to porous silica or
ceramic
Acetonitrile and phosphate-perchlorate buffer
(700:300, v/v) adjusted to pH 2.0 with
phosphoric acid
UV,
220 nm
FXD hydrochloride tablets 4.6 mm  10 cm, packing octadecyl silane bonded to porous silica or
ceramic
Acetonitrile and phosphate-perchlorate buffer
(7:3, v/v)
UV,
220 nm
FXD and pseudoephedrine
hydrochloride
extended-release tablets
4.6 mm  25 cm, packing sulfonated ﬂuorocarbon polymer coated on
a solid spherical core
4.6 mm  5 cm, packing sulfonated ﬂuorocarbon polymer coated on a
solid spherical core connected in series to a 4.6 mm  25 cm, packing
phenyl groups bonded with porous silica
Monobasic sodium phosphate-phosphoric acid
buffer (pH 2.00 ± 0.05): acetonitrile (55:45, v/v)
Methanol : acetate/1-octanesulphonate buffer
adjusted with glacial acid to pH of 4.6 (35:65, v/v)
UV,
210 nm
UV,
215 nm
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3.2. This complex was passed through anhydrous Na2SO4, and
measured at 440 nm [40]. Spectrophotometric methods have been
developed and validated for the determination of FXD hydrochlo-
ride in pure form or pharmaceutical formulations using bromophe-
nol blue, bromothymol blue, bromocresol green and bromocresol
purple [41]. These methods involved the formation of colored chlo-
roform extractable ion-associate complexes in acidic medium. The
extracted complexes showed absorbance maxima at 411, 414, 409,and 411 nm, for the above-mentioned dyes respectively. Kumar
et al. [42] described a method for the determination of FXD hydro-
chloride in bulk and pharmaceutical dosage forms. The method is
based on the formation of chloroform-extractable pale yellow color
complex formed with bromothymol blue at pH 2.6, which can be
estimated at 412 nm. KET fumarate in tablet formulation has been
estimated by the formation of chloroform extractable colored com-
plexes with 2-nitroso-napthol-4-sulphonic acid, rhodizonic acid
and azocarmine G [35,43]. The extracted complexes showed
6 M.E. El-Kommos et al. / Analytical Chemistry Research 3 (2015) 1–12absorbance maxima at 436.5, 489.5 and 540 nm, respectively.
El-Kousy and Bebawy [32] described a method for estimation of
KET and LOR, based on the formation of orange red ion pair
complexes with molybdenum thiocyanate measured at 469.5 nm
in dichloromethane. Furthermore, a visible spectrophotometric
method has been developed for estimation of LOR from tablet
formulation via formation of chloroform extractable colored
complex with bromophenol blue at 413 nm and with cobalt
thiocyanate at 624.5 nm [44].
5.2.2.4. Miscellaneous. Basavaiah and Charan [12] proposed a spec-
trophotometric method for assay of CTZ. To a ﬁxed concentration
of mercury (II)-diphenylcarbazone complex, different amounts of
the drug were added and the decrease in absorbance of the formed
complex was measured at 540 nm. Gazy et al. [37] developed a
spectrophotometric method for determination of CTZ, FXD and
LOR; through the base-catalyzed condensation of mixed anhy-
drides of organic acids (citric acid/acetic anhydride) where the ter-
tiary amino group in these drugs acts as the basic catalyst.
5.2.3. Flow injection analysis
A ﬂow injection chemiluminescence (CL) method was estab-
lished for the determination of KET. CL was observed when potas-
sium hexacyanoferrate (III) reacted with the mixture of calcein and
KET [45]. Also, ﬂow injection method was introduced for determi-
nation of KET fumarate in pure samples and in its pharmaceutical
preparations by using PVC membrane selective electrodes, where
KET tetraphenylborate was used as ion exchanger over the pH
range 2.0–8.0 [46]. A mixture of LOR and pseudoephedrine sulfate
was determined in pharmaceutical samples using non-linear sec-
ond-order data generated by a pH-gradient ﬂow injection analysis
(FIA) system with diode-array detection [47].
5.2.4. Spectroﬂuorimetric methods
Gazy et al. [37] suggested spectroﬂuorimetric method for deter-
mination of CTZ, FXD and LOR in pure and their commercial dosage
forms. This method was based on the reaction of these drugs with
eosin giving ion-pair complex, measurable directly without extrac-
tion. CTZ, EBS, and FXD were determined through charge transfer
complexation of these drugs with some p acceptors namely CLA,
tetracyanoethylene (TCNE), and DDQ to give highly ﬂuorescent
derivatives [48]. A rapid and simple ﬂuorimetric procedure for the
determination of trace amounts of CTZ hydrochloride in pharma-
ceutical formulations has been developed, through measuring the
ﬂuorescence intensity at kex. 230 nm, kem. 297 nm [49]. Also, CTZ
dihydrochloride was determined by measuring its anti-ﬂuores-
cence quenching effect on rhodamine B-sodium tetraphenylborate
system at kex. 491, kem. 610 nm [50]. Furthermore, a stability-
indicating micelle-enhanced spectroﬂuorimetric method for deter-
mination of LOR in dosage forms was developed. This method is
based on investigation of the ﬂuorescence spectral behavior in a
sodium dodecyl sulphate micellar system [51]. On the other hand,
validated stability-indicating spectroﬂuorimetric methods were
developed for the determination of EBS in pharmaceutical prepara-
tions depending on reaction with its tertiary amino group [52,23].
First method involves condensation of the drug with mixed anhy-
drides (citric and acetic anhydrides) producing a product with
intense ﬂuorescence, which was measured at kex. 388 nm, kem.
496 nm [52]. The second method described the quantitative
ﬂuorescence quenching effect on eosin upon addition of the studied
drug, at kex. 457 nm, kem. 553 nm. This method was extended to
third method where the ﬁrst and second derivative synchronous
spectroﬂuorimetric method (FDSFS & SDSFS) were used for the
simultaneous analysis of EBS or FXD in presence of alkaline, acidic,
and UV degradation products [23]. A sensitive ﬂuorimetric method
was reported for the assay of FXD hydrochloride in a pharmaceuti-cal formulation and biological ﬂuids using silver nanoparticles as a
ﬂuorescence probe where the drug caused considerable quenching
of the emission band of silver NPs due to the formation of complex
[53]. On the other hand, the interactions between LOR and bovine
and human serum albumin were studied using tryptophan ﬂuores-
cence quenching method [54].
5.2.5. Chemiluminescence methods
A method has been developed for the analysis of FXD in phar-
maceutical formulations, using a tris (1,10-phenanthroline)-ruthe-
nium(II) [Ru(phen)32+] peroxydisulphate chemiluminescence
system in a multichip device [55]. Also, the luminescence sensiti-
zation of europium (Eu3+) by complexation with FXD HCl has been
studied at kex. 276 nm, kem. 615 nm [56].
5.2.6. Atomic absorption spectrometric methods
El-Kousy and Bebawy [32] developed an atomic absorption
spectrometric method for the determination of KET and LOR. This
method depends on the reaction of these drugs with cobalt thiocy-
anate reagent at pH 2 to give ternary complexes. These complexes
are readily extracted with organic solvent and estimated by indi-
rect atomic absorption method via the determination of the cobalt
content in the formed complex after extraction in 0.1 M hydrochlo-
ric acid.
5.3. Chromatographic methods
5.3.1. Thin layer chromatographic methods
Many reported TLC-spectrodensitometric methods [29,57–64]
for separation and determination of NSAs in pure, pharmaceutical
dosage forms and in biological ﬂuids are listed in Table 5.
5.3.2. High-performance liquid chromatographic methods
There is an impressive increase in the use of high-performance
liquid chromatography for determination of NSAs in the last thirty
years. HPLC has been used frequently in all ﬁelds of NSAs research.
These methods are based on different stationary phases (silica, C8,
C18, cyanopropyl and Alpha1-acid glycoprotein), different mobile
systems and using UV, ﬂuorescence or tandem mass for detection.
There are many reported HPLC methods for separation and quanti-
tative determination of NSAs in pure, pharmaceutical dosage forms
(Supplementary Table 6) [14,25,30,65–102] and in biological ﬂuids
(Supplementary Table 7) [103–156].
5.3.3. Gas chromatographic methods
GC/MS assay for the anti-anaphylactic agent KET in human
plasma was described. This method is based on negative ion chem-
ical ionization, utilizing the electrophoric nature of the underiv-
atized drug [157]. On the other hand, GC/MS with selected ion
monitoring has been used for the quantiﬁcation of KET and its
metabolites in human plasma and urine samples [158,159]. A val-
idated GC/MS method for determination of total amount of KET in
human plasma has been described using pizotifen as an internal
standard (IS) [160]. Furthermore, a sensitive gas–liquid chromato-
graphic (GLC) method has been developed for the determination of
LOR and its active metabolite in human plasma, using a nitrogen-
phosphorus detector and a fused-silica capillary column [161].
GC/MS method for the determination of LOR and pheniramine in
human serum has been developed [162]. Capillary gas chromatog-
raphy methods were proposed for the determination of residual
organic solvents-diethyl ether, iso-propyl alcohol, acetonitrile, 2-
methylpropanol-2, ethyl acetate, tetrahydrofuran, cyclohexane, tri-
ethylamine, toluene in LOR samples. A capillary column was used
with temperature programmed control and dimethyl formamide
(DMF) as the solvent [163]. Also, Agilent capillary column was used
with ﬂame ionization detector (FID) detector and nitrogen as the
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ionization (CI)-MS analysis, with He carrier gas, and temperature
programming from 70 C to 300 C at 20 C/min [165].
5.4. Capillary electrophoretic methods
A capillary electrophoretic method for the determination of CTZ
in Zyrtec tablet, syrup, and oral drops was developed using 10%
methanol at pH 8.5. The voltage applied, 28 kV produced signals
that were detected at 200 nm using phenobarbital sodium as an
IS [166]. A sulfated beta-cyclodextrin (sulfated beta-CD)-mediated
capillary electrophoresis method was described for the enantiosep-
aration of CTZ in bulk and human plasma samples and enantio-
meric purity evaluation of levocetirizine (R-enantiomer) in
pharmaceutical tablets using a chiral cefazolin as an IS. The enan-
tioseparation of the drug was performed in a borate buffer (5 mM,
pH 8.7) with 1% w/v sulfated beta-CD as chiral selector at 10 kV
[167]. Also, Enantioselective analysis of CTZ in pharmaceuticals
by cyclodextrin-mediated capillary electrophoresis was developed
using FXD as an IS [168]. On the other hand, chiral separation of
CTZ in tablets was studied by CD-mediated CE using a 75 mM tri-
ethanolamine-phosphate buffer (pH 2.5) containing 0.4 mg/mL
heptakis (2,3-diacetyl-6-sulfato)-beta-CD and 10% acetonitrile.
Online UV detection was performed at 214 nm, at 20 kV [169].
Capillary zone electrophoresis (CZE) method has been developed
for the simultaneous separation and determination of CTZ dihydro-
chloride, paracetamol, and phenylpropanolamine HCl in tablets
using 10 mM sodium tetraborate (pH 9.0) and an uncoated
fused-silica capillary at the applied voltage of 20 kV. UV detection
was performed at 195 nm, with Ibuprofen as IS [170]. Nojavan andTable 5
TLC-densitometric methods for determination of the studied NSAs in pure, pharmaceutica
Drug(s) Stationary phase M
CTZ
CTZ with pseudoephedrine (stability-indicating study) Silica gel 60 F254 Et
CTZ. 2 HCl with ambroxol HCl in tablets (stability-
indicating study)
Silica gel 60 GF254 CC
CTZ with ambroxol in tablets Silica gel 60 F254 M
CTZ Silica gel 60 F254,
aluminum oxide 60 F254
Ch
FXD
FXD with
Pseudoephedrine Silica gel 60 F254 Et
(7
Acetaminophen Silica gel 60 F254 Et
(7
KET
KET Aluminum oxide 60 F254 Et
KET fumarate in tablets Silica gel 60 F254 Et
(1
KET with
Pseudoephedrine Silica gel 60 F254 Et
(1
Acetaminophen Silica gel 60 F254 Et
(1
LOR
LOR and preservatives in syrups
(LOR–sodium benzoate mixtures) Silica gel 60 F254 n-
ac
(LOR–methylparaben–propylparaben mixtures) Silica gel 60 F254 Et
di
LOR in presence of degradation products, tablets and
syrups, (stability-indicating study)
Silica gel 60 F254 Ch
A
LOR with
Pseudoephedrine Silica gel 60 F254 Et
(1
Acetaminophen Silica gel 60 F254 EtFakhari [171] developed a method for chiral separation and quan-
titation of CTZ and hydroxyzine by maltodextrin-mediated CE in
human plasma. Capillary electrophoresis method with UV detec-
tion was developed and validated for the quantitation of FXD
hydrochloride in capsules using an uncoated fused-silica capillary
at 20 kV potential and 20 mM Na2B4O710 H2O buffer [172]. Mikus
et al. [173] used capillary electrophoresis for determination of FXD
in tablets with and without CDs as analyte carriers. A capillary
electrophoretic method was developed for the determination of
LOR in tablets using 24 mmol/L glycine as a carrier cation,
1.6 mmol/L citric acid and 84 mmol/L acetic acid as counter ions
at pH 3.2 with UV detection at 240 nm [174]. Capella-Peiró et al.
[175] used a full factorial design to optimize the experimental con-
ditions of a CZE method aimed at achieving simultaneous separa-
tion and quantiﬁcation of the antihistamines brompheniramine,
chlorpheniramine, cyproheptadine, diphenhydramine, doxyla-
mine, hydroxyzine, and LOR in urine and serum samples, using
phosphate buffer pH 2.0 and 5 kV at 214 nm.
5.5. Electrochemical methods
A method was successfully applied to the determination of
CTZ in pharmaceutical preparations using direct potentiometric
method [176]. Javanbakht et al. [177] developed a biomimetic
potentiometric sensor using molecularly imprinted polymer for
the CTZ assay in tablets and biological ﬂuids. A multi-walled
carbon nanotube (MWCNT) ﬁlm-modiﬁed glassy carbon
electrode (GCE) was constructed for the determination of CTZ
dihydrochloride in urine samples using cyclic voltammetry
(CV). The MWCNT ﬁlm has shown an obvious electrocatalyticl dosage forms and in biological ﬂuids.
obile phase Analytical
wavelength (nm)
References
hyl acetate–methanol-ammonia (7:1.5:1, v/v/v) 240 nm [57]
l4–Chloroform–Methanol (3:5:2, v/v/v) 230 nm [58]
ethanol–0.067 m KH2PO4 (35:65, v/v) 231 nm [59]
loroform–ethyl acetate (1:1, v/v) 254 nm [60]
hyl acetate:methanol:ammonia 33%;
: 2: 1, v/v/v).
217 nm [61]
hyl acetate:methanol:ammonia 33%;
:2:1, v/v/v)
233 nm [61]
hyl acetate–butan-2-one-toluene, (7:3, v/v). 254 nm [60]
hyl acetate–methanol–liquid ammonia
50:15:1, v/v/v)
301 nm [62]
hyl acetate:methanol:ammonia 33%;
5:1:2, v/v/v)
218 nm [61]
hyl acetate:methanol:ammonia 33%;
5:0.3:2, v/v/v)
272 nm [61]
Butyl acetate–carbon tetrachloride–acetic
id–acetonitrile (3:6:0.2:3, v/v/v/v)
240 nm [63]
hyl acetate–n-hexane–methanol–ammonia–
ethylamine (1:4:0.8:0.4:2, v/v/v/v)
275 nm
loroform–ethyl acetate–acetone (5:7:7, v/v/v) 200–400 nm [64]
mmonia–methanol (3:200, v/v) 246 nm. [29]
hyl acetate:methanol:ammonia 33%;
5:0.3:2, v/v/v)
218 nm [61]
hyl acetate:ammonia 33%; (15:2, v/v) 251 nm [61]
8 M.E. El-Kommos et al. / Analytical Chemistry Research 3 (2015) 1–12activity towards oxidation of CTZ, since it facilitates the electron
transfer and signiﬁcantly enhances its oxidation peak current
[178]. On the other hand, the electrochemical oxidation of CTZ
dihydrochloride at different pHs and concentrations using CV
and differential pulse voltammetry with a GCE was studied. This
study indicated that CTZ was susceptible to oxidation. The best
results were obtained in phosphate buffer of pH 8 [179]. Khater
et al. [180] constructed new modiﬁed carbon paste electrodes
for determination of KET fumarate in its pure and pharmaceuti-
cal preparations. Furthermore, an electro-analytical method has
been developed for the determination of the KET in biological
ﬂuids by continuous square wave adsorptive stripping
voltammetry on a ultra-gold microelectrode in aqueous solution
with phosphate buffer as supporting electrolyte (pH 2.3) and an
accumulation potential of 300 mV [181]. Li et al. [182] proposed
an electrochemiluminescence method for determination of KET
fumarate on GCE modiﬁed with platinum-multi-walled carbon
nanotube modiﬁed electrode. Also, ion-transfer voltammetry at
a nitrobenzene/water interface was performed to study the
ion-transfer reaction and the adsorption of histamine and KET.
Ion-transfer voltammograms showed that KET gave an anodic
wave at a potential less positive than that of histamine [183].
Ghoneim et al. [184] described the polarographic behavior of
LOR in human plasma at the mercury electrode using buffer
solution of pH 6, and a sensitive differential pulse stripping
voltammetric method based on controlled adsorptive accumula-
tion of LOR on a hanging mercury drop electrode for its direct
determination at nanomolar concentrations without nitration
of the drug using 0.1 M sodium hydroxide solution as a
supporting electrolyte, accumulation potential 1.2 V and pulse
amplitude 100 mV. Norouzi and Ganjali [185] introduced the
fast Fourier transformation continuous cyclic voltammetry at a
gold microelectrode in a ﬂowing-solution system for
determination of LOR in pharmaceuticals, the parameter values
were set to 80 V/s for the scan rate, 0.7 s for the accumulation
time, 300 mV for the accumulation potential, and 2 for
the pH.
6. Conclusion
Our review article is a comprehensive review of different meth-
ods for the analysis of commonly prescribed non-sedating antihis-
tamines. The review covers most of the methods described for the
analysis of cetirizine, ebastine, fexofenadine, ketotifen and lorata-
dine in pure forms, in different pharmaceutical dosage forms and
in biological ﬂuids. The review covers the period from 1991 till
now. Chromatographic, spectroscopic, electrochemical, and titri-
metric methods are presented. 63.2% of the reported analytical
methods are chromatographic methods as shown in the following
chart:Disclosure
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